Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vebreltinib in recurrent secondary glioblastoma with PTPRZ1-MET fusion
NCT06105619Phase 3Active, not recruiting
- Sponsor
- Beijing Pearl Biotechnology Co., Ltd.
- Start
- Oct 2018
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of vebreltinib in glioblastoma (GBM) (2 arms), sponsored by Beijing Pearl Biotechnology Co., Ltd. Primary endpoint: Overall Survival at 5 years. Started Oct 2018; status: active, not recruiting.
02
Drugs
vebreltinib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT06105619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06105619.